美国 · SEC FORM 4
Relay Therapeutics, Inc.
RLAY · Nasdaq · CIK 0001812364 · Healthcare · Biotechnology
内部人信号
0 qualifying P purchase groups
当前 180 天评分窗口
32 同一窗口内观察到的 Form 4 交易行
26 sales · 6 期权、代扣税、授予、赠与或其他交易行
为什么没有活跃信号?
评分构成
活跃窗口内没有合资格买入,因此不计算分数。缺失的输入不会被当作零分或看空信号。
为什么没有分数?
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示,不会形成负分。
卖出和其他 Form 4 活动会单独显示,不会形成负面买入信号。没有买入不会被评分为看空。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型;卖出仅作为背景。
—
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后,这些模块才会启用。
信号历史
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2020-07-20 · Patel Sanjiv.
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据,不影响内部人信号。
- 空头股数
- 46,746,942
- 上期报告
- 44,487,428
- 日均成交量
- 3,712,736
- 回补天数
- 12.6
FINRA 结算日:2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数,每月两个结算日之后约一周公布;不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2020-07-20 | Rubin Jami | 买入 (P) | Common Stock | 25,000 | USD 20.00 | USD 500,000 | SEC 申报 ↗ |
| 2020-07-20 | Patel Sanjiv | 买入 (P) | Common Stock | 25,000 | USD 20.00 | USD 500,000 | SEC 申报 ↗ |
| 2020-07-20 | Murcko Mark | 买入 (P) | Common Stock | 25,000 | USD 20.00 | USD 500,000 | SEC 申报 ↗ |
| 2020-07-20 | INGRAM DOUGLAS S | 买入 (P) | Common Stock | 25,000 | USD 20.00 | USD 500,000 | SEC 申报 ↗ |
| 2020-07-20 | Adams Brian | 买入 (P) | Common Stock | 10,000 | USD 20.00 | USD 200,000 | SEC 申报 ↗ |
Form 4 申报证据
50 transaction lines in the latest 365-day window; 385 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-10-07 | Patel Sanjiv | 卖出 (S) | Common Stock | 48,199 | USD 18.10 | USD 872,402 | SEC 申报 ↗ |
| 2026-10-06 | Catinazzo Thomas | 卖出 (S) | Common Stock | 17,717 | USD 18.59 | USD 329,322 | SEC 申报 ↗ |
| 2026-09-08 | Patel Sanjiv | 卖出 (S) | Common Stock | 48,199 | USD 18.94 | USD 912,889 | SEC 申报 ↗ |
展开近期 Form 4 证据 (30 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-10-07 | Patel Sanjiv | 卖出 (S) | Common Stock | 48,199 | USD 18.10 | USD 872,402 | SEC 申报 ↗ |
| 2026-10-06 | Catinazzo Thomas | 卖出 (S) | Common Stock | 17,717 | USD 18.59 | USD 329,322 | SEC 申报 ↗ |
| 2026-09-08 | Patel Sanjiv | 卖出 (S) | Common Stock | 48,199 | USD 18.94 | USD 912,889 | SEC 申报 ↗ |
| 2026-09-08 | Catinazzo Thomas | 卖出 (S) | Common Stock | 17,717 | USD 18.94 | USD 335,560 | SEC 申报 ↗ |
| 2026-09-08 | Bergstrom Donald A | 卖出 (S) | Common Stock | 8,530 | USD 18.97 | USD 161,814 | SEC 申报 ↗ |
| 2026-08-26 | Rahmer Peter | 卖出 (S) | Common Stock | 4,508 | USD 20.03 | USD 90,295 | SEC 申报 ↗ |
| 2026-08-25 | SB INVESTMENT ADVISERS (UK) LTD; SOFTBANK VISION FUND (AIV M2) L.P.; SVF Pauling (Cayman) Ltd | 卖出 (S) | Common Stock | 6,000,000 | USD 19.40 | USD 116,400,000 | SEC 申报 ↗ |
| 2026-08-17 | Patel Sanjiv | 卖出 (S) | Common Stock | 48,199 | USD 20.33 | USD 979,886 | SEC 申报 ↗ |
| 2026-08-14 | Catinazzo Thomas | 卖出 (S) | Common Stock | 17,717 | USD 19.74 | USD 349,734 | SEC 申报 ↗ |
| 2026-07-28 | Rahmer Peter | 卖出 (S) | Common Stock | 748 | USD 18.61 | USD 13,920 | SEC 申报 ↗ |
| 2026-07-28 | Catinazzo Thomas | 卖出 (S) | Common Stock | 1,459 | USD 18.61 | USD 27,152 | SEC 申报 ↗ |
| 2026-07-28 | Bergstrom Donald A | 卖出 (S) | Common Stock | 2,237 | USD 18.61 | USD 41,631 | SEC 申报 ↗ |
| 2026-07-07 | Patel Sanjiv | 卖出 (S) | Common Stock | 48,199 | USD 19.58 | USD 943,736 | SEC 申报 ↗ |
| 2026-07-06 | Catinazzo Thomas | 卖出 (S) | Common Stock | 17,717 | USD 18.69 | USD 331,131 | SEC 申报 ↗ |
| 2026-07-06 | Bergstrom Donald A | 卖出 (S) | Common Stock | 8,660 | USD 18.71 | USD 162,029 | SEC 申报 ↗ |
| 2026-06-30 | Patel Sanjiv | 奖励/授予 (A) | Common Stock | 3,056 | USD 6.95 | USD 21,239 | SEC 申报 ↗ |
| 2026-06-30 | Rahmer Peter | 卖出 (S) | Common Stock | 50,000 | USD 19.09 | USD 954,500 | SEC 申报 ↗ |
| 2026-06-30 | Rahmer Peter | 奖励/授予 (A) | Common Stock | 3,056 | USD 6.95 | USD 21,239 | SEC 申报 ↗ |
| 2026-06-22 | Catinazzo Thomas | 卖出 (S) | Common Stock | 187,163 | USD 16.97 | USD 3,176,865 | SEC 申报 ↗ |
| 2026-06-22 | Catinazzo Thomas | 期权行权/转换 (M) | Common Stock | 169,446 | USD 4.93 | USD 834,669 | SEC 申报 ↗ |
| 2026-06-22 | Bergstrom Donald A | 卖出 (S) | Common Stock | 93,456 | USD 16.94 | USD 1,583,145 | SEC 申报 ↗ |
| 2026-06-22 | Bergstrom Donald A | 期权行权/转换 (M) | Common Stock | 93,456 | USD 4.12 | USD 385,039 | SEC 申报 ↗ |
| 2026-05-14 | Catinazzo Thomas | 卖出 (S) | Common Stock | 17,717 | USD 12.86 | USD 227,841 | SEC 申报 ↗ |
| 2026-04-28 | Rahmer Peter | 卖出 (S) | Common Stock | 753 | USD 14.79 | USD 11,137 | SEC 申报 ↗ |
| 2026-04-28 | Catinazzo Thomas | 卖出 (S) | Common Stock | 972 | USD 14.79 | USD 14,376 | SEC 申报 ↗ |
| 2026-04-28 | Bergstrom Donald A | 卖出 (S) | Common Stock | 1,490 | USD 14.79 | USD 22,037 | SEC 申报 ↗ |
| 2026-04-09 | Catinazzo Thomas | 卖出 (S) | Common Stock | 1,800 | USD 15.00 | USD 27,000 | SEC 申报 ↗ |
| 2026-04-09 | Catinazzo Thomas | 期权行权/转换 (M) | Common Stock | 1,800 | USD 5.22 | USD 9,396 | SEC 申报 ↗ |
| 2026-04-07 | Catinazzo Thomas | 卖出 (S) | Common Stock | 17,717 | USD 13.01 | USD 230,498 | SEC 申报 ↗ |
| 2026-03-09 | Catinazzo Thomas | 卖出 (S) | Common Stock | 17,717 | USD 10.06 | USD 178,233 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | RLAY |
| CIK | 0001812364 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2836 Biological Products, (No Diagnostic Substances) |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 385 transaction lines from 2020-07-20 to 2026-10-07 5 P purchase lines · 273 S sale lines · 107 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.